200 related articles for article (PubMed ID: 30448598)
21. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
[TBL] [Abstract][Full Text] [Related]
22. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E;
Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Pan CQ; Duan Z; Dai E; Zhang S; Han G; Wang Y; Zhang H; Zou H; Zhu B; Zhao W; Jiang H;
N Engl J Med; 2016 Jun; 374(24):2324-34. PubMed ID: 27305192
[TBL] [Abstract][Full Text] [Related]
26. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Suzuki Y; Kumada H
Drug Des Devel Ther; 2014; 8():869-73. PubMed ID: 25061278
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
Marcellin P; Buti M; Krastev Z; de Man RA; Zeuzem S; Lou L; Gaggar A; Flaherty JF; Massetto B; Lin L; Dinh P; Subramanian GM; McHutchison JG; Flisiak R; Gurel S; Dusheiko GM; Heathcote EJ
J Hepatol; 2014 Dec; 61(6):1228-37. PubMed ID: 25046847
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW
Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Marcellin P; Zoulim F; Hézode C; Causse X; Roche B; Truchi R; Pauwels A; Ouzan D; Dumortier J; Pageaux GP; Bourlière M; Riachi G; Zarski JP; Cadranel JF; Tilliet V; Stern C; Pétour P; Libert O; Consoli SM; Larrey D
Dig Dis Sci; 2016 Oct; 61(10):3072-3083. PubMed ID: 26821154
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B;
Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
Lee HJ; Kim SJ; Kweon YO; Park SY; Heo J; Woo HY; Hwang JS; Chung WJ; Lee CH; Kim BS; Suh JI; Tak WY; Jang BK
PLoS One; 2018; 13(1):e0190581. PubMed ID: 29329305
[TBL] [Abstract][Full Text] [Related]
32. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Ahn SS; Chon YE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
Clin Mol Hepatol; 2014 Sep; 20(3):261-6. PubMed ID: 25320729
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
[TBL] [Abstract][Full Text] [Related]
35. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial.
Yim HJ; Kim IH; Suh SJ; Jung YK; Kim JH; Seo YS; Yeon JE; Kim CW; Kwon SY; Park SH; Lee MS; Um SH; Byun KS
J Viral Hepat; 2018 Nov; 25(11):1321-1330. PubMed ID: 29772084
[TBL] [Abstract][Full Text] [Related]
36. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.
Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Kim JH; Jung SW; Byun SS; Shin JW; Park BR; Kim MH; Kim CJ; Park NH
Int J Clin Pharm; 2015 Dec; 37(6):1228-34. PubMed ID: 26364195
[TBL] [Abstract][Full Text] [Related]
38. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
[TBL] [Abstract][Full Text] [Related]
40. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
Yuen MF; Ahn SH; Lee KS; Um SH; Cho M; Yoon SK; Lee JW; Park NH; Kweon YO; Sohn JH; Lee J; Kim JA; Lai CL; Han KH
J Hepatol; 2015 Mar; 62(3):526-32. PubMed ID: 25450709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
